Generic Sulfamylon® Launches

On February 2, 2013, Par Pharmaceutical received final FDA approval for and commenced shipping the generic equivalent for Mylan’s branded product, Sulfamylon® (mafenide acetate) topical solution. Sulfamylon® had estimated total U.S. annual sales of approximately $8 million.

Sulfamylon® is indicated as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.